Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Trials and Treatment in Advanced Melanoma

July 31st 2019

Recommendations for Molecular Testing in Melanoma

July 31st 2019

BRAF and MEK in Melanoma

July 31st 2019

Developments in the Management of Stage III Melanoma

July 31st 2019

Unmet Needs in BRAF+ NSCLC

July 31st 2019

Treatment Considerations for BRAF+ NSCLC

July 31st 2019

Molecular Testing in NSCLC

July 31st 2019

Targeting BRAF in NSCLC

July 31st 2019

Dr. Polsky on the Predictive Value of ctDNA in BRAF-Mutant Melanoma

July 30th 2019

David Polsky, MD, PhD, Alfred W. Kopf, MD Professor of Dermatologic Oncology, Ronald O. Perelman Department of Dermatology, professor, Department of Pathology, and director, Pigmented Lesion Service, NYU Langone’s Perlmutter Cancer Center, discusses the predictive value of circulating tumor DNA (ctDNA) in BRAF-mutant melanoma.

Dr. Long on Dabrafenib/Trametinib in BRAF V600E-Mutant Melanoma

July 26th 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, co-medical director of Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, University of Sydney, discusses results from the 5-year analysis of the combination of dabrafenib and trametinib in patients with BRAF V600E-mutant melanoma.

Smoking, Vitamin D Deficiency Correlate to Ulcerated Melanoma

July 25th 2019

Ulcerated melanoma is associated with worse outcomes and appears to be driven in part by systemic inflammation, which is more common in smokers, obese individuals, and those with vitamin D deficiency.

Dr. Khushalani on Goals for the CA045-001 Trial in Melanoma

July 25th 2019

Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center, discusses the plans for the CA045-001 trial, an international, multicenter study that is comparing bempegaldesleukin plus nivolumab versus nivolumab monotherapy in patients with previously untreated, unresectable, or metastatic melanoma.

Dr. Flaherty on the COLUMBUS Trial Updates in BRAF-Mutant Melanoma

July 24th 2019

Keith T. Flaherty, MD, discusses an update on overall survival in COLUMBUS, a randomized phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.

ctDNA Monitoring Carries Clinical Validity in Advanced BRAF-Mutant Melanoma

July 23rd 2019

David Polsky, MD, PhD, discusses findings from an analysis in patients with BRAF-mutant, unresectable, metastatic melanoma, as well as the next steps for validating these findings and potentially using circulating tumor DNA to help inform treatment decisions.

Management of Relapsed/Refractory Metastatic Melanoma

July 18th 2019

Managing Melanoma Brain Metastases

July 18th 2019

Metastatic Melanoma: Key Trial Updates

July 18th 2019

Immunotherapy vs TKIs in BRAF+ Metastatic Melanoma

July 18th 2019

Melanoma Progression Following Adjuvant Therapy

July 18th 2019

Adjuvant Therapy for Locally Advanced Melanoma

July 18th 2019